The spray-dried formulations for Ethris’ mRNA vaccine candidates will be developed at Lonza’s Bend, Ore., Center of Excellence in accordance with GMP standards.

Magnified View of Lipid Nanoparticles | Image Credit: ©Aniwat - stock.adobe.com

Organic Nanoparticle-Based Drug-Delivery Systems as Alternatives to Lipid Nanoparticles

By Cynthia A. Challener

March 9th 2025

Exosomes, polymeric nanoparticles, and DNA nanostructures offer many potential advantages.

Text sign showing Industry News. Business photo text delivering news to the general public or a target public | Image Credit: © Artur - © Artur - stock.adobe.com

EMA Approves TAKHZYRO for Additional Subcutaneous Administration Option to Treat Hereditary Angioedema

By Feliza Mirasol

March 7th 2025

Takeda’s TAKHZYRO (lanadelumab) is now approved in Europe as a subcutaneous injection treatment for hereditary angioedema in patients 12 years old and above and in adults.

Lonza Partners with Iconovo to Formulate and Develop an Intranasal Biologic

By Feliza Mirasol

January 14th 2025

Lonza will develop spray-dried formulations for an intranasally delivered biologic using a reformulated biologic drug candidate for obesity in Iconovo’s pipeline.

Science laboratory test tubes, laboratory equipment | Image Credit: © BillionPhotos.com - © BillionPhotos.com - stock.adobe.com

Orexo Collaborates with Abera on Nasal Powder Vaccines

By Feliza Mirasol

December 19th 2024

Using Orexo’s powder-based drug delivery technology, the companies will develop mucosal vaccines in an inhaled formulation.

...

6 7 8 9 10

About Us

Advertise

Editorial Information

Do Not Sell My Personal Information

Terms and Conditions

Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777